Akzo Nobel’s life science business unit Diosynth RTP, which was acquired from Covance, benefits from €18m investment in its upstream manufacturing capacity. The company has brought forward an increase in large-scale cGMP capacity at Diosynth’s new production facilities located in Oss, The Netherlands.
Among services offered by Diosynth Biotechnology, are:
Recombinant Protein Biopharmaceuticals:
Synthetic Phamaceutical Peptides:
Customers looking for large-scale cGMP production of therapeutic proteins for late phase clinical and commercial use could anticipate technology transfer activities to start during 2002, allowing necessary scale-up and validation activities to commence during 2003.
Diosynth’s state-of-the-art downstream processing facility featuring more than 20 clean rooms opened in Oss, the Netherlands in 2000 and inspected by the FDA. Diosynth is constructing an adjacent upstream processing facility. It features cGMP cell culture capacity to 18,000-L working volume and cGMP microbial fermentation production trains of 5,000-L and 10,000-L working volume. The new facility will be fully validated and available for cGMP production in late 2003.
Diosynth Inc. completed its acquisition of Covance Biotechnology in October 2001. Diosynth manufactures active biopharmaceutical ingredients for clients in the pharmaceutical industry under contract manufacturing agreements.
Diosynth has been a producer of Active Pharmaceutical Ingredients for seventy-five years and provides process development and cGMP manufacturing services to many of the world’s major pharmaceutical and biotechnology companies.
